Additive Effect of Oral Steroid with Topical Nonsteroidal Antiinflammatory Drug for Preventing Cystoid Macular Edema after Cataract Surgery in Patients with Epiretinal Membrane
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the additive effect of oral steroid with topical nonsteroidal anti-inflammatory drug(NSAID) on cystoid macular edema (CME) in patients with epiretinal membrane (ERM) after cataract surgery. Methods: Medical records of subjects who underwent uneventful cataract surgery (n = 1,349) were retrospectivelyreviewed; among these patients, those with pre-existing ERM (n = 81) were included. Patients were dividedinto two groups: one group had postoperative administration of oral steroid for 1 week (n = 45) and theother group did not have oral steroid administration (n = 36). Changes in macular thickness and incidence ofCME were compared in both groups. Topical NSAIDs were administered in both groups for 1 month postoperatively. Definite CME and probable CME were defined by changes in retinal contour with or without cystoidchanges. Change in central macular thickness of more than three standard deviations (≥90.17 μm) was definedas possible CME. Macular thickness was measured at 1 month after the operation by optical coherencetomography. Results: The incidence of definite, probable, and possible CME were 2.22%, 4.44%, and 8.89% with the use ofsteroid and 2.78%, 5.56%, and 8.33% without steroid, respectively (p = 0.694, p = 0.603, and p = 0.625), andregardless of treatment group, the incidences in these patients were higher compared to incidences in wholesubjects (1.26%, 2.30%, and 4.32%; p = 0.048, p = 0.032, and p = 0.038, respectively). The differences inmacular thickness were not statistically different between the two groups. Average changes of central fovealthickness in 3 mm and 6 mm zone were 29.29 μm, 35.93 μm, and 38.02 μm with the use of steroid and 32.25μm, 44.08 μm, and 45.39 μm without steroid (p = 0.747, p = 0.148, and p = 0.077, respectively). Conclusions: This study suggests that administration of oral steroid may not have a synergistic effect in reductionof CME and retinal thickness in patients with pre-existing ERM after cataract surgery, when topicalNSAIDs are applied.
Abstract
Purpose: To investigate the additive effect of oral steroid with topical nonsteroidal anti-inflammatory drug(NSAID) on cystoid macular edema (CME) in patients with epiretinal membrane (ERM) after cataract surgery. Methods: Medical records of subjects who underwent uneventful cataract surgery (n = 1,349) were retrospectivelyreviewed; among these patients, those with pre-existing ERM (n = 81) were included. Patients were dividedinto two groups: one group had postoperative administration of oral steroid for 1 week (n = 45) and theother group did not have oral steroid administration (n = 36). Changes in macular thickness and incidence ofCME were compared in both groups. Topical NSAIDs were administered in both groups for 1 month postoperatively. Definite CME and probable CME were defined by changes in retinal contour with or without cystoidchanges. Change in central macular thickness of more than three standard deviations (≥90.17 μm) was definedas possible CME. Macular thickness was measured at 1 month after the operation by optical coherencetomography. Results: The incidence of definite, probable, and possible CME were 2.22%, 4.44%, and 8.89% with the use ofsteroid and 2.78%, 5.56%, and 8.33% without steroid, respectively (p = 0.694, p = 0.603, and p = 0.625), andregardless of treatment group, the incidences in these patients were higher compared to incidences in wholesubjects (1.26%, 2.30%, and 4.32%; p = 0.048, p = 0.032, and p = 0.038, respectively). The differences inmacular thickness were not statistically different between the two groups. Average changes of central fovealthickness in 3 mm and 6 mm zone were 29.29 μm, 35.93 μm, and 38.02 μm with the use of steroid and 32.25μm, 44.08 μm, and 45.39 μm without steroid (p = 0.747, p = 0.148, and p = 0.077, respectively). Conclusions: This study suggests that administration of oral steroid may not have a synergistic effect in reductionof CME and retinal thickness in patients with pre-existing ERM after cataract surgery, when topicalNSAIDs are applied.
참고문헌 (32)
- Irvine SR, "A newly defined vitreous syndrome following cataract surgery", Am J Ophthalmol, 36, pp.599~619 (1953)
- Flach AJ, "The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery", Trans Am Ophthalmol Soc, 96, pp.557~634 (1998)
- Yonekawa Y, "Pseudophakic cystoid macular edema", Curr Opin Ophthalmol, 23, pp.26~32 (2012)
- Gass JD, "Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study", Arch Ophthalmol, 76, pp.646~661 (1966)
- Henderson BA, "Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment", J Cataract Refract Surg, 33, pp.1550~1558 (2007)
- Kusbeci T, "Evaluation of cystoid macular edema using optical coherence tomography and fundus fluorescein angiography after uncomplicated phacoemulsification surgery", Curr Eye Res, 37, pp.327~333 (2012)
- Perente I, "Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography", Curr Eye Res, 32, pp.241~247 (2007)
- Giansanti F, "Evaluation of macular thickness after uncomplicated cataract surgery using optical coherence tomography", Eur J Ophthalmol, 23, pp.751~756 (2013)
- Kim SJ, "A method of reporting macular edema after cataract surgery using optical coherence tomography", Retina, 28, pp.870~876 (2008)
- Biro Z, "OCT measurements on the foveal and perifoveal retinal thickness on diabetic patients af ter phacoemulsification and IOL implantation", Eye (Lond), 24, pp.639~647 (2010)
- Shimura M, "Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes", J Ocul Pharmacol Ther, 23, pp.284~291 (2007)
- Miyake K, "The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation", Invest Ophthalmol Vis Sci, 48, pp.5647~5652 (2007)
- O’Brien TP, "Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care", Curr Med Res Opin, 21, pp.1131~1137 (2005)
- Wolf EJ, "Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac", J Cataract Refract Surg, 33, pp.1546~1549 (2007)
- Miyake K, "Nepafenac 0.1%versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery", J Cataract Refract Surg, 37, pp.1581~1588 (2011)
- Elsawy MF, "Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery", Clin Ophthalmol, 7, pp.1245~1249 (2013)
- Wittpenn JR, "A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients", Am J Ophthalmol, 146, pp.554~560 (2008)
- Donnenfeld ED, "Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery", Am J Ophthalmol, 151, pp.420.e1~426.e1 (2011)
- Shah AS, "Cataract surgery and diabetes", Curr Opin Ophthalmol, 21, pp.4~9 (2010)
- Sijssens KM, "Long-term ocular complications in aphakic versus pseudophakic eyes of children with juvenile idiopathic arthritis-associated uveitis", Br J Ophthalmol, 94, pp.1145~1149 (2010)
- Rashid S, "Progression of diabetic retinopathy and maculopathy after phacoemulsification surgery", Int Ophthalmol Clin, 50, pp.155~166 (2010)
- Williams GA, "Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome", Am J Ophthalmol, 147, pp.1048~1054 (2009)
- Jonas JB, "Intravitreal triamcino lone acetonide for pseudophakic cystoid macular edema", Am J Ophthalmol, 136, pp.384~386 (2003)
- Shelsta HN, "Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update", Retina, 31, pp.4~12 (2011)
- Yuksel B, "Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema", Ocul Immunol Inflamm, pp.1~7 (2016)
- Guo S, "Management of pseudophakic cystoid macular edema", Surv Ophthalmol, 60, pp.123~137 (2015)
- Stanford MR, "Diagnostic and therapeutic approach to patients with retinal vasculitis", Int Ophthalmol Clin, 40, pp.69~83 (2000)
- Jabs DA, "Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel", Am J Ophthalmol, 130, pp.492~513 (2000)
- Heier JS, "Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema", Ophthalmology, 107, pp.2034~2038 (2000)
- Benitah NR, "Pseudophakic cystoid macular edema", Int Ophthalmol Clin, 50, pp.139~153 (2010)
- Folkman J, "Angiostatic steroids: method of discovery and mechanism of action", Ann Surg, 206, pp.374~383 (1987)
- Meacock WR, "Steroid prophylaxis in eyes with uveitis undergoing phacoemulsification", Br J Ophthalmol, 88, pp.1122~1124 (2004)